A study presented at a conference in Vienna found that the appropriate dose of pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI) varies depending on the root cause of the insufficiency. Patients with EPI due to pancreatic cancer or pancreatectomy require significantly more enzyme replacement than those with insufficiency due to chronic or acute pancreatitis. Additionally, the study showed that the need to include a proton-pump inhibitor (PPI) in treatment also varies by condition. The study aims to provide clearer guidance on the optimal dosing of PERT for different causes of EPI to achieve the therapeutic goal of resolving nutritional deficiencies and symptoms associated with insufficiency.
Source link
Optimal PERT Dose Varies by Primary Pancreatic Disease
